Land: Den Europæiske Union
Sprog: engelsk
Kilde: EMA (European Medicines Agency)
clomipramine hydrochloride
Virbac S.A.
QN06AA04
Clomipramine
Dogs
Psychoanaleptics
As an aid in the treatment of separation related disorders in dogs manifested by destruction and inappropriate elimination (defecation and urination) and only in combination with behavioural modification techniques.
Revision: 18
Authorised
1998-04-01
15 B. PACKAGE LEAFLET 16 PACKAGE LEAFLET: CLOMICALM 5 MG TABLETS FOR DOGS CLOMICALM 20 MG TABLETS FOR DOGS CLOMICALM 80 MG TABLETS FOR DOGS 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder and manufacturer responsible for batch release: VIRBAC 1ère avenue – 2065 m – LID 06516 Carros France 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Clomicalm 5 mg tablets for dogs Clomicalm 20 mg tablets for dogs Clomicalm 80 mg tablets for dogs Clomipramine hydrochloride 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) 5 mg Clomipramine hydrochloride (equivalent to 4.5 mg Clomipramine) 20 mg Clomipramine hydrochloride (equivalent to 17.9 mg Clomipramine) 80 mg Clomipramine hydrochloride(equivalent to 71.7 mg Clomipramine) 5 mg tablet: Brownish-grey, oval-oblong, divisible. Scored on both sides. 20 mg tablet: Brownish-grey, oval-oblong, divisible. One side bears the imprint ‘C/G’, the other ‘G/N’ and scored on both sides. 80 mg tablet: Brownish-grey, oval-oblong, divisible. One side bears the imprint ‘I/I’, the other no imprint and scored on both sides. 4. INDICATION(S) As an aid in the treatment of separation related disorders manifested by destruction and inappropriate elimination (defaecation and urination) and only in combination with behavioural modification techniques. 5. CONTRAINDICATIONS Do not use in case of known hypersensitivity to clomipramine and related tricyclic antidepressants. Do not use in male breeding dogs. 6. ADVERSE REACTIONS 17 Clomicalm may very rarely cause vomiting, changes in appetite, lethargy or an elevation in liver enzymes, which is reversible when the product is discontinued. Hepato-biliary disease has been reported, especially with pre-existing conditions, and concurrent administrations of drugs metabolized via the hepatic system. Vomiting may be reduced by co-administration with a small quantity of food. The frequency of adverse reaction Læs hele dokumentet
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Clomicalm 5 mg tablets for dogs Clomicalm 20 mg tablets for dogs Clomicalm 80 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet of Clomicalm contains: ACTIVE SUBSTANCE: Clomipramine hydrochloride 5 mg (equivalent to 4.5 mg Clomipramine) Clomipramine hydrochloride 20 mg (equivalent to 17.9 mg Clomipramine) Clomipramine hydrochloride 80 mg (equivalent to 71.7 mg Clomipramine) EXCIPIENTS: For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets. 5 mg tablet: Brownish-grey, oval-oblong, divisible. Scored on both sides. 20 mg tablet: Brownish-grey, oval-oblong, divisible. One side bears the imprint ‘C/G’, the other ‘G/N’ and scored on both sides. 80 mg tablet: Brownish-grey, oval-oblong, divisible. One side bears the imprint ‘I/I’, the other no imprint and scored on both sides. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dog 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES As an aid in the treatment of separation-related disorders in dogs manifested by destruction and inappropriate elimination (defaecation and urination) and only in combination with behavioural modification techniques. 4.3 CONTRAINDICATIONS Do not use in case of known hypersensitivity to clomipramine and related tricyclic antidepressants. Do not use in male breeding dogs. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES The efficacy and safety of Clomicalm has not been established in dogs weighing less than 1.25 kg or under six months of age. 4.5 SPECIAL PRECAUTIONS FOR USE 3 Special precautions for use in animals It is recommended that Clomicalm be administered to dogs with cardiovascular dysfunction or epilepsy with caution and only after an assessment of the benefit risk ratio. Because of its potential anticholinergic properties, Clomicalm should also be used with care in dogs with narrow angle glaucoma, reduced gastrointestinal motility or urinary retention. Clomicalm should be used under veterin Læs hele dokumentet